The Mesoblast (ASX:MSB) share price has tumbled 25% in a month. What's going on?

It's been a tough month on the ASX for Mesoblast.

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price has had a hard time of it lately. Its struggles seem to have been born from a 17% single-day plunge last month, from which the company – whose stock is also listed on the Nasdaq exchange under the ticker NASDAQ: MESO – hasn't yet managed to recover.

In early morning trade on Wednesday, the Mesoblast share price is $1.36. That's 20% lower than it was this time last month.

Let's take a look at what's been weighing on the biotechnology company recently.

What's dragging the Mesoblast share price lower?

The Mesoblast share price has been feeling down since it announced a Swiss healthcare company dumped its product in mid-December.

Novartis terminated an agreement that could have seen Mesoblast's remestemcel-L used to treat COVID-19-induced acute respiratory distress syndrome (ARDS).

As The Motley Fool noted at the time, the agreement's cancellation saw around US$1.2 billion of Mesoblast's potential earnings washed down the drain.

Of course, the agreement's termination might have been expected by some.

It was put in place less than a month before Mesoblast released news its randomised control trial treating ventilator-dependent patients with ARDS due to COVID-19 was called off early after it became apparent it was unlikely to meet its primary endpoint.

The Mesoblast share price recovered some of its losses on 16 December. That's when the company released positive news of a trial using remestemcel-L to treat chronic back pain.

Its shares gained 11% that day, but they didn't manage to hold onto the boost.

In fact, the Mesoblast share price has already shed 3.55% year to date. It's also 47% lower than it was this time last year.

On top that that, Mesoblast remains one of the most shorted stocks on the ASX. The Motley Fool's most recent weekly breakdown of shorting found 9.1% of the company's shares were in the hands of short sellers.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »